Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

about

All-in-one processing of heterogeneous human cell grafts for gene and cell therapy.Improving cancer outcomes through international collaboration in academic cancer treatment trials.A novel approach for determining cancer genomic breakpoints in the presence of normal DNA

P2860

Q30387995-135B9252-99D1-4F16-950C-51FDA88983E8 Q33561197-8750F1F0-8B50-42AF-98B7-DD1BE6965599 Q35741860-AE59DE03-22BC-40DE-84B2-5474A7659977

P2860

Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

Item

http://www.wikidata.org/entity/Q36652555

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

@ast

Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

@en

type

Item

label

Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

@ast

Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

@en

prefLabel

Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

@ast

Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

@en

P1476

Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

@en

P2093

Andrea Biondi

http://www.w3.org/2001/XMLSchema#string

Giovanni Cazzaniga

http://www.w3.org/2001/XMLSchema#string

Giuseppe Gaipa

http://www.w3.org/2001/XMLSchema#string

Vincenzo Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Minimal residual disease in leukaemia patients.

Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).

Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia.

P304

512-521

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07853890600978123

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17101542

http://www.w3.org/2001/XMLSchema#string

Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

about

P2860

P2860

Monitoring of minimal residual disease in leukemia, advantages and pitfalls.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698